The authors reply
- PMID: 41631942
- DOI: 10.1097/CCM.0000000000006985
The authors reply
Conflict of interest statement
Dr. Granholm’s institution received funding from the Novo Nordisk Foundation and Sygeforsikringen “danmark”; he disclosed off-label use of haloperidol. Dr. Collet received support for article research from the Novo Nordisk Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.
References
-
- Chen S-C, Yeh C-H: Haloperidol in intensive care delirium: A trade-off between survival and functional recovery. Crit Care Med 2026; 54:372–373
-
- Poulsen LM, Mortensen CB, Andersen-Ranberg NC, et al.: Functional status after delirium in the ICU: A 1-year follow-up of the Agents Intervening against Delirium in the ICU (AID-ICU) trial. Crit Care Med 2025; 53:e2222–e2232
-
- Andersen-Ranberg NC, Poulsen LM, Perner A, et al.; AID-ICU Trial Group: Haloperidol for the treatment of delirium in ICU patients. N Engl J Med 2022; 387:2425–2435
-
- Colantuoni E, Li X, Hashem MD, et al.: A structured methodology review showed analyses of functional outcomes are frequently limited to “survivors only” in trials enrolling patients at high risk of death. J Clin Epidemiol 2021; 137:126–132
-
- Mortensen CB, Andersen-Ranberg NC, Poulsen LM, et al.: Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium. Intensive Care Med 2024; 50:103–113
LinkOut - more resources
Full Text Sources
